Supriya Lifescience Share Price Today | Stock Price & Supriya Lifescience Share Screener
As of October 5, 2026, the live Supriya Lifescience share price (NSE: SUPRIYA) is ₹899.55 on NSE and ₹899.75 on BSE, down 3.38% from the previous close, with shares trading between ₹882.20 and ₹944.95 in today's trading session, and a 52-week range of ₹553.35–₹1,052.50. Check SUPRIYA 52-week performance for the annual price range and momentum. Use the Supriya Lifescience stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Supriya Lifescience opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Over the trailing twelve months the company reported revenue of ₹884 and net income of ₹198, with EBITDA of ₹301, an operating margin of 33.0% and a profit margin of 22.4%.
Supriya Lifescience Share Price Chart
Track the current stock price of Supriya Lifescience with an interactive chart. Analyse SUPRIYA share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Supriya Lifescience stock quote in one place.
The quote of ₹899.55 sits between the 52-week low of ₹553.35 and the 52-week high of ₹1,052.50, and the latest session moved -3.38% from the previous close.
Supriya Lifescience Company Profile - Fundamental Screener
Screen Supriya Lifescience company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for SUPRIYA shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Pharmaceuticals industry, and it trades under ISIN INE07RO01027.
Company Details
Classification
Identifiers and Leadership
Supriya Lifescience Balance Sheet Screener
Screen SUPRIYA balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2026, total assets were ₹1,357, up from ₹1,117 in 2025.
Latest statistics put total assets at ₹1,357 and shareholder funds at ₹1,198.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Assets |
||||||||||
| Total Assets | 1,357 | 1,117 | 921 | 820 | 735 | 446 | 336 | 253 | 245 | 241 |
| Current Assets | 532 | 442 | 398 | 465 | 498 | 266 | 196 | 133 | 120 | 115 |
| Fixed Assets | 689 | 453 | 310 | 262 | 190 | 100 | 99 | 85 | 91 | 89 |
Liabilities |
||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 38 | 33 | 29 | 25 | 19 | 31 | 32 | 24 | 45 | 51 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Shareholders' Equity |
||||||||||
| Total Equity | 1,198 | 997 | 815 | 700 | 616 | 269 | 149 | 94 | 55 | 46 |
| Share Capital | 16 | 16 | 16 | 16 | 16 | 15 | 15 | 15 | 15 | 15 |
| Reserves & Surplus | 1,182 | 981 | 799 | 683 | 600 | 254 | 134 | 79 | 40 | 31 |
Supriya Lifescience Income Statement Screener - Profit & Revenue Analysis
Screen Supriya Lifescience income statement and profit fundamentals. Analyze SUPRIYA quarterly results. Supriya Lifescience reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For None-None, revenue was ₹884 and net profit was ₹198, equal to earnings per unit of ₹24.70, at an operating margin of 33%.
In that period expenses were ₹583, interest cost ₹2 and tax ₹59. The next period listed, 2026-March, shows revenue of ₹839 and net profit of ₹209.
| Item | None-None | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March | 2015-March |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | |||||||||||||
| Revenue | 884 | 839 | 706 | 581 | 470 | 538 | 396 | 323 | 286 | 222 | 191 | 172 | 140 |
| Expenses | 583 | 534 | 436 | 397 | 332 | 316 | 218 | 213 | 213 | 191 | 166 | 150 | 121 |
Operating Costs and Margins | |||||||||||||
| EBITDA | 301 | 306 | 271 | 184 | 138 | 222 | 178 | 110 | 73 | 31 | 25 | 22 | 20 |
| Operating Profit % | 33.00% | 36.00% | 37.00% | 30.00% | 28.00% | 40.00% | 44.00% | 32.00% | 23.00% | 10.00% | 9.00% | 12.00% | 12.00% |
| Depreciation | 31 | 28 | 20 | 16 | 12 | 10 | 7 | 6 | 5 | 5 | 5 | 4 | 3 |
| Interest | 2 | 2 | 2 | 2 | 3 | 4 | 4 | 7 | 10 | 11 | 12 | 10 | 7 |
Profit and Earnings | |||||||||||||
| Profit Before Tax | 268 | 275 | 249 | 166 | 124 | 207 | 167 | 96 | 57 | 15 | 8 | 8 | 10 |
| Tax | 59 | 66 | 61 | 47 | 34 | 55 | 44 | 23 | 18 | 6 | 2 | 2 | 2 |
| Net Profit | 198 | 209 | 188 | 119 | 90 | 152 | 124 | 73 | 39 | 9 | 6 | 6 | 8 |
| EPS | 24.70 | 25.98 | 23.35 | 14.80 | 11.16 | 18.86 | 16.89 | 10.02 | 5.39 | 1.19 | 3.87 | 3.89 | 16.82 |
Supriya Lifescience Cash Flow Screener - Liquidity Fundamentals
Screen SUPRIYA cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2026-March, operating activities generated ₹186.
Over the same period, investing activities used ₹176 and financing activities used ₹10.
| Item | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations and Investing | ||||||||||
| Operating Activities | 186 | 165 | 113 | 64 | 49 | 76 | 117 | 49 | 28 | 27 |
| Investing Activities | -176 | -152 | -174 | -124 | -60 | -47 | -25 | 5 | -5 | -27 |
Financing and Net Cash | ||||||||||
| Financing Activities | -10 | -8 | -22 | -10 | 150 | -15 | -29 | -50 | -20 | -2 |
| Net Cash Flow | 0 | 4 | -83 | -70 | 139 | 15 | 62 | 4 | 3 | -2 |
Supriya Lifescience Shareholding Pattern Screener
See Supriya Lifescience shareholding pattern with promoter, FII, and DII holdings. Check Supriya Lifescience promoter holding and ownership changes for SUPRIYA on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Mar, promoters held 68.30%, foreign institutions 5.16%, domestic institutions 5.70% and the public 16.22%, spread across 81,161 shareholders.
The shareholder count was 81,161 in 2026-Mar, compared with 82,082 in 2026-Jun.
| Item | 2026-Mar | 2026-Jun | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 68.30% | 68.30% | 68.30% | 68.30% | 68.30% | 68.30% | 68.30% | 68.30% |
Institutional Investors | ||||||||
| FII Holding | 5.16% | 6.19% | 7.19% | 6.78% | 5.46% | 5.20% | 5.36% | 4.95% |
| DII Holding | 5.70% | 5.30% | 4.26% | 4.86% | 5.22% | 5.01% | 5.30% | 5.48% |
Government, Public and Others | ||||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 16.22% | 15.98% | 16.40% | 16.39% | 16.77% | 16.66% | 17.06% | 17.19% |
| Other Holding | 4.63% | 4.23% | 3.85% | 3.67% | 4.25% | 4.83% | 3.98% | 4.08% |
| Shareholder Count | 81,161 | 82,082 | 91,051 | 91,928 | 87,912 | 85,099 | 87,980 | 89,621 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Supriya Lifescience. Supriya Lifescience dividend yield can be compared with peers and other stocks in the market.
The latest dividend recorded was ₹1.00 per unit for 2026-March, a yield of 0.10%, compared with ₹1.00 for 2025-March.
Dividends are listed for 10 periods, with the three most recent payouts at ₹1.00, ₹1.00 and ₹0.80 per unit.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹1.00 | 0.10% |
| 2025-March | ₹1.00 | 0.18% |
| 2024-March | ₹0.80 | 0.11% |
| 2023-March | ₹0.60 | 0.18% |
| 2022-March | ₹0.60 | 0.32% |
| 2021-March | ₹0.54 | 0.11% |
| 2020-March | ₹0.00 | 0.00% |
| 2019-March | ₹0.00 | 0.00% |
| 2018-March | ₹0.00 | 0.00% |
| 2017-March | ₹0.00 | 0.00% |
Supriya Lifescience Stock Index Membership - Nifty & Sensex
See which indices include Supriya Lifescience stock. Check SUPRIYA index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
The company is listed in 5 indices, including BSE 1000.
Among the benchmarks tracked are BSE 1000, BSE INDEX BSE HC, BSE INDEX SMLCAP, NIFTY MICROCAP250.
Complete Index List
Supriya Lifescience Market Events Screener - Corporate Actions
Get Supriya Lifescience corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Supriya Lifescience stock events that may affect SUPRIYA share price, along with derivatives, futures and options activity and sector gainers.
15 corporate actions are listed, the most recent entry being Annual General Meeting dated September 24, 2026, with a record date of September 24, 2026.
It is followed by Dividend dated September 4, 2026 and Quarterly Result Announcement dated August 13, 2026.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-09-24 | 2026-09-24 | Annual General Meeting | NA | 26.43% |
| 2026-09-04 | 2026-09-04 | Dividend | ₹ 1.00 /share | 8.03% |
| 2026-08-13 | 2026-08-13 | Quarterly Result Announcement | NA | -9.00% |
| 2026-05-27 | 2026-05-27 | Quarterly Result Announcement | NA | 8.24% |
| 2026-02-09 | 2026-02-09 | Quarterly Result Announcement | NA | 0.36% |
| 2025-11-12 | 2025-11-12 | Quarterly Result Announcement | NA | -6.66% |
| 2025-09-24 | 2025-09-24 | Annual General Meeting | NA | 11.37% |
| 2025-09-04 | 2025-09-05 | Dividend | ₹ 1.00 /share | -11.70% |
| 2025-08-13 | 2025-08-13 | Quarterly Result Announcement | NA | -0.96% |
| 2025-05-27 | 2025-05-27 | Quarterly Result Announcement | NA | 5.82% |
| 2025-01-24 | 2025-01-24 | Quarterly Result Announcement | NA | 9.11% |
| 2024-10-28 | 2024-10-28 | Quarterly Result Announcement | NA | -1.41% |
| 2024-09-27 | 2024-09-27 | Annual General Meeting | NA | -6.20% |
| 2024-09-20 | 2024-09-21 | Dividend | ₹ 0.80 /share | 74.84% |
| 2023-09-15 | 2023-09-15 | Dividend | ₹ 0.60 /share | 13.53% |
Supriya Lifescience Competitors Screener - Peer Stocks Comparison
Screen SUPRIYA competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 447,476 | 36.44 | 61,674 | 12.69% | 11,565 | 47.42 |
| Divis Laboratories | 250,363 | 86.51 | 11,067 | 13.95% | 2,568 | 58.71 |
| Torrent Pharmaceuticals | 186,152 | 85.91 | 13,886 | 20.34% | 2,138 | 48.14 |
| Zydus Life Science | 120,798 | 26.32 | 27,658 | 17.64% | 5,026 | 61.81 |
| Cipla | 111,426 | 33.44 | 29,045 | 2.24% | 3,870 | 44.03 |
| Laurus Labs | 106,838 | 99.70 | 6,868 | 22.01% | 890 | 58.00 |
| Mankind Pharma | 105,107 | 48.73 | 14,636 | 14.85% | 1,938 | 64.24 |
| Dr Reddys Laboratories | 104,492 | 32.05 | 35,059 | 3.90% | 4,158 | 69.59 |
| Aurobindo Pharma | 97,682 | 26.36 | 34,145 | 5.56% | 3,503 | 54.69 |
| Lupin | 93,829 | 16.99 | 29,039 | 26.75% | 5,356 | 34.02 |
Supriya Lifescience Company Announcements - News & Reports Screener
Screen SUPRIYA latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated October 4, 2026.
The next most recent announcements are dated October 1, 2026 and October 1, 2026.
| Date | Update | Actions |
|---|---|---|
| 2026-10-04 | Closure of Trading Window | - |
| 2026-10-01 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | - |
| 2026-10-01 | Shareholder Meeting / Postal Ballot-Outcome of AGM | - |
| 2026-09-29 | Announcement Under Regulation 30 Of SEBI (LODR) Regulations 2015. | - |
| 2026-09-27 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-09-11 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-09-02 | Intimation Under Regulation 30 Regarding Letter Dispatched To The Shareholders Of The Company | - |
| 2026-09-02 | Announcement Under Regulation 30 Of SEBI (LODR) Regulations 2015. | - |
| 2026-09-02 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-09-01 | Business Responsibility and Sustainability Reporting (BRSR) | - |
| 2026-09-01 | Notice Of 18Th Annual General Meeting Of The Company. | - |
| 2026-09-01 | Reg. 34 (1) Annual Report. | - |
| 2026-08-27 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-26 | Record Date For Determining Members Eligible To Receive Dividend For The Financial Year 2025-26. | - |
| 2026-08-22 | Shareholder Meeting / Postal Ballot-Scrutinizer"s Report | - |
| 2026-08-22 | Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot | - |
| 2026-08-18 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | - |
| 2026-08-14 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |
| 2026-08-14 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-13 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
Frequently Asked Questions
How is the company valued right now?
The current quote is ₹899.55, within a 52-week range of ₹553.35 to ₹1,052.50. The P/E ratio is 39.95 and the P/B ratio is 6.62, with earnings per unit of ₹25.98. Market capitalisation stands at ₹7,927.96 Cr and the dividend yield is 0.10%. The company operates in the Healthcare sector, in the Pharmaceuticals industry, so compare these ratios with its sector peers in the table above.
About This Data
Quotes are sourced from the NSE and the BSE. Key statistics were last updated on October 5, 2026. This page covers 10 balance sheet periods, 13 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.